

Christopher T Ritchlin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3641723/christopher-t-ritchlin-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

202
papers

11,563
citations

53
h-index

105
g-index

243
ext. papers

13,917
ext. citations

6.7
avg, IF

6.5
L-index

#	Paper	IF	Citations
202	Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2).. <i>Rheumatology and Therapy</i> , 2022 , 1	4.4	0
201	Single-cell transcriptomics of popliteal lymphatic vessels and peripheral veins reveals altered lymphatic muscle and immune cell populations in the TNF-Tg arthritis model.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 64	5.7	1
200	Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022 , 7, 17-23	1.1	0
199	Does biologic therapy impact the development of PsA among patients with psoriasis?. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
198	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	1
197	Navigating the diverse immune landscapes of psoriatic arthritis. <i>Seminars in Immunopathology</i> , 2021 , 43, 279-290	12	0
196	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. <i>Rheumatology</i> , 2021 , 60, 5337-5350	3.9	4
195	Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints. <i>Rheumatology</i> , 2021 , 60, iv16-iv27	3.9	0
194	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1815-1823	4.1	3
193	Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. <i>Rheumatology</i> , 2021 , 60, 2109-2121	3.9	10
192	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1254-1268	4.5	42
191	Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. <i>Pharmacology & Therapeutics</i> , 2021 , 107925	13.9	1
190	Differences in oxylipin profile in psoriasis versus psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 200	5.7	1
189	Axial spondyloarthritis: new advances in diagnosis and management. <i>BMJ, The</i> , 2021 , 372, m4447	5.9	15
188	Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	6
187	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 238-243	8.1	6
186	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNF-inhibitor-experienced. <i>RMD Open</i> , 2021 , 7,	5.9	10

185	Moving the Goalpost Toward Remission: The Case for Combination Immunomodulatory Therapies in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1574-1578	9.5	
184	New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2112-2122.e3	4.3	2
183	Demonstration of Functional Deficiencies in Popliteal Lymphatic Vessels From TNF-Transgenic Mice With Inflammatory Arthritis. <i>Frontiers in Physiology</i> , 2021 , 12, 745096	4.6	2
182	Altered Lymphatic Vessel Anatomy and Markedly Diminished Lymph Clearance in Affected Hands of Patients With Active Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1447-1455	9.5	7
181	Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1759-1770	9.5	6
180	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020 , 395, 1496-1505	4.0	83
179	Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNF inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2020 , 395, 1115-1125	4.0	93
178	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020 , 395, 427-440	4.0	65
177	New onset of axial spondyloarthritis in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. <i>Clinical Rheumatology</i> , 2020 , 39, 1829-1838	3.9	3
176	Moving Toward Precision Medicine in Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020 , 96, 19-24	4.1	2
175	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , 2020 , 96, 53-57	4.1	6
174	Lineage tracing reveals evidence of a popliteal lymphatic muscle progenitor cell that is distinct from skeletal and vascular muscle progenitors. <i>Scientific Reports</i> , 2020 , 10, 18088	4.9	3
173	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. <i>Current Rheumatology Reports</i> , 2020 , 22, 78	4.9	6
172	Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020 , 2, 543-554	3.5	2
171	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1704-1716	4.5	31
170	Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. <i>Arthritis Care and Research</i> , 2020 , 72, 1579-1588	4.7	4
169	Go with the flow-hidden vascular passages in bone. <i>Nature Metabolism</i> , 2019 , 1, 173-174	14.6	5
168	Selective Sexual Dimorphisms in Musculoskeletal and Cardiopulmonary Pathologic Manifestations and Mortality Incidence in the Tumor Necrosis Factor-Transgenic Mouse Model of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1512-1523	9.5	13

167	Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials. <i>Journal of Rheumatology</i> , 2019 , 46, 1458-1467	4.1	10
166	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 153-166	8.1	111
165	Measuring outcomes in ankylosing spondylitis: pearls and pitfalls. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 109-117	5.3	5
164	Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology. <i>Current Rheumatology Reviews</i> , 2019 , 15, 277-289	1.6	14
163	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019 , 95, 54-57	4.1	6
162	Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1112-1124	9.5	94
161	iNOS dependent and independent phases of lymph node expansion in mice with TNF-induced inflammatory-erosive arthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 240	5.7	9
160	TNF-Induced Interstitial Lung Disease in a Murine Arthritis Model: Accumulation of Activated Monocytes, Conventional Dendritic Cells, and CD21/CD23 B Cell Follicles Is Prevented with Anti-TNF Therapy. <i>Journal of Immunology</i> , 2019 , 203, 2837-2849	5.3	5
159	Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. <i>BMC Rheumatology</i> , 2019 , 3, 52	2.9	14
158	Strategies to Improve Outcomes in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2019 , 21, 72	4.9	13
157	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019 , 4, 31-58	1.1	6
156	Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. <i>Rheumatology</i> , 2019 , 58, 1025-1033	3.9	4
155	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 5-32	9.5	178
154	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019 , 71, 2-29	4.7	137
153	The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. <i>Rheumatology</i> , 2019 , 58, 197-205	3.9	40
152	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. <i>Journal of Rheumatology</i> , 2018 , 45, 378-384	4.1	27
151	Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 94-106	8.1	62
150	Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions. <i>Calcified Tissue International</i> , 2018 , 102, 559-574	3.9	20

149	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). <i>Arthritis Research and Therapy</i> , 2018 , 20, 47	5.7	69
148	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 3-17	2.4	320
147	Thy1 is a positive regulator of osteoblast differentiation and modulates bone homeostasis in obese mice. <i>FASEB Journal</i> , 2018 , 32, 3174-3183	0.9	16
146	Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>RMD Open</i> , 2018 , 4, e000638	5.9	4
145	Psoriasis: Psychosomatic, somatopsychic, or both?. <i>Clinics in Dermatology</i> , 2018 , 36, 698-703	3	10
144	Disease Modification in Psoriatic Arthritis. <i>Current Treatment Options in Rheumatology</i> , 2018 , 4, 197-213	1.3	
143	Chronic social stress Ameliorates psoriasiform dermatitis through upregulation of the Hypothalamic-Pituitary-Adrenal axis. <i>Brain, Behavior, and Immunity</i> , 2018 , 68, 238-247	16.6	11
142	Opportunities and challenges in the treatment of psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 440-452	5.3	7
141	Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 1107-1123	2.1	24
140	Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2018 , 45, 1389-1396	4.1	51
139	Brief Report: Treatment of Tumor Necrosis Factor-Transgenic Mice With Anti-Tumor Necrosis Factor Restores Lymphatic Contractions, Repairs Lymphatic Vessels, and May Increase Monocyte/Macrophage Egress. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1187-1193	9.5	19
138	Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017 , 376, 957-970	59.2	586
137	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 79-87	2.4	341
136	Targeting Notch-Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1469-1480	6.3	58
135	Basic and Translational Science: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 679-683	4.1	1
134	International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 684-685	4.1	3
133	GRAPPA Trainees Symposium 2016: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 661-667	4.1	0
132	Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2017 , 44, 1151-1158	4.1	11

131	Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017 , 376, 2095-6	59.2	60
130	Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Arthritis Care and Research</i> , 2017 , 69, 1692-1699	4.7	62
129	Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2017 , 56, 1993-2003	3.9	92
128	Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Osteoclast Differentiation via the Ca ²⁺ /NFATc1 Axis. <i>Journal of Cellular Physiology</i> , 2017 , 232, 2538-2549	7	16
127	Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 119-128	5.4	39
126	MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E7917-E7926	11.5	36
125	Tofeforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies. <i>Journal of Rheumatology</i> , 2016 , 43, 1637-42	4.1	14
124	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 743-750	8.1	52
123	Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1984-1988	2.4	101
122	Relationship Between Lymph Node Volume and Pain Following Certolizumab Therapy for Rheumatoid Arthritis Flare: A Pilot Study. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2016 , 9, 203-208	2.3	6
121	DC-STAMP: A Key Regulator in Osteoclast Differentiation. <i>Journal of Cellular Physiology</i> , 2016 , 231, 2402-7		59
120	Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>Rheumatology and Therapy</i> , 2016 , 3, 91-102	4.4	92
119	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1060-71	9.5	485
118	New therapies for psoriasis and psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 204-10	5.3	52
117	A critical role for the protein kinase PKK in the maintenance of recirculating mature B cells and the development of B1 cells. <i>Immunology Letters</i> , 2016 , 172, 67-78	4.1	3
116	Mechanisms of Bone Remodelling in Psoriatic Arthritis 2016 , 111-126		
115	Targeting the interleukin-23/17 axis in axial spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 359-67	5.3	36
114	Bone remodeling in psoriasis and psoriatic arthritis: an update. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 66-75	5.3	18

113	GRAPPA Trainees Symposium 2015: A Report from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016 , 43, 952-8	4.1	3
112	Lymphatic imaging to assess rheumatoid flare: mechanistic insights and biomarker potential. <i>Arthritis Research and Therapy</i> , 2016 , 18, 194	5.7	19
111	Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1812-1822	4.7	19
110	The role of the lymphatic system in inflammatory-erosive arthritis. <i>Seminars in Cell and Developmental Biology</i> , 2015 , 38, 90-7	7.5	31
109	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2015 , 386, 1137-46	4.0	566
108	Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. <i>Journal of Rheumatology</i> , 2015 , 42, 1439-42	4.1	45
107	GRAPPA Treatment Recommendations: An Update from the GRAPPA 2014 Annual Meeting and GRAPPA Meeting Adjacent to the 2014 ACR Meeting. <i>Journal of Rheumatology</i> , 2015 , 42, 1052-1055	4.1	4
106	IL12/IL23 Inhibition in the Treatment of Psoriatic Arthritis. <i>Current Treatment Options in Rheumatology</i> , 2015 , 1, 197-209	1.3	3
105	Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 111-7	5.3	27
104	Etiology and Pathogenesis of Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 643-63	2.4	45
103	Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. <i>American Journal of Human Genetics</i> , 2015 , 97, 816-36	11	185
102	An Integrative Approach to Biomarker Development in Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2015 , 93, 43-7		1
101	Prevalence of chronic axial pain, inflammatory back pain, and spondyloarthritis in diagnosed psoriasis. <i>Arthritis Care and Research</i> , 2015 , 67, 829-35	4.7	17
100	Validation of power Doppler versus contrast-enhanced magnetic resonance imaging quantification of joint inflammation in murine inflammatory arthritis. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 690-4	6.3	9
99	Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. <i>Arthritis Care and Research</i> , 2015 , 67, 1739-49	4.7	71
98	GRAPPA Trainees Symposium 2014: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015 , 42, 1016-1020	4.1	3
97	Etiology and pathogenesis of psoriatic arthritis 2015 , 998-1007		
96	The joint in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S20-5	2.2	6

95	Immunologic advances reveal new targets in psoriasis and psoriatic arthritis. <i>Discovery Medicine</i> , 2015 , 20, 169-75	2.5	5
94	Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 2290-4	4.1	36
93	Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA. <i>Journal of Rheumatology</i> , 2014 , 41, 2273-6	4.1	33
92	Patients with rheumatoid arthritis in clinical remission manifest persistent joint inflammation on histology and imaging studies. <i>Journal of Rheumatology</i> , 2014 , 41, 2153-60	4.1	29
91	Psoriatic enthesitis: an update from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1220-3	4.1	6
90	Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 515-26	5.4	23
89	Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1000-6	2.4	211
88	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 6-16	2.4	308
87	Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. <i>New England Journal of Medicine</i> , 2014 , 370, 2295-306	59.2	298
86	GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1237-9	4.1	20
85	Spondyloarthritis: Closing the gap in psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 704-5	8.1	3
84	GRAPPA Trainees Symposium 2013: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1200-5	4.1	7
83	Transient decrease in human peripheral blood myeloid dendritic cells following influenza vaccination correlates with induction of serum antibody. <i>Immunological Investigations</i> , 2014 , 43, 606-15	2.9	2
82	In vivo quantification of lymph viscosity and pressure in lymphatic vessels and draining lymph nodes of arthritic joints in mice. <i>Journal of Physiology</i> , 2014 , 592, 1213-23	3.9	49
81	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 990-9	2.4	465
80	Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy. <i>PLoS ONE</i> , 2014 , 9, e110657	3.7	13
79	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. <i>Lancet, The</i> , 2013 , 382, 780-9	4.0	557
78	Mechanistic insights from animal models of psoriasis and psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2013 , 15, 377	4.9	13

77	Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow. <i>Arthritis and Rheumatism</i> , 2013 , 65, 130-8		39
76	Troponin T3 expression in skeletal and smooth muscle is required for growth and postnatal survival: characterization of Tnnt3(tm2a(KOMP)Wtsi) mice. <i>Genesis</i> , 2013 , 51, 667-75	1.9	11
75	Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 79-92	6.3	64
74	Consensus guidelines for the management of plaque psoriasis. <i>Archives of Dermatology</i> , 2012 , 148, 95-102		135
73	Biomarkers to Diagnose Early Arthritis in Patients with Psoriasis. <i>Psoriasis Forum</i> , 2012 , 18a, 48-56		
72	Altered bone biology in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2012 , 14, 349-57	4.9	24
71	Biomarker development in psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , 2012 , 89, 57-60		6
70	GRAPPA Trainees Symposium 2011: a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , 2012 , 39, 2184-8	4.1	5
69	Biomarkers of radiographic progression in psoriatic arthritis: a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , 2012 , 39, 2189-92	4.1	9
68	Biomarkers to Diagnose Early Arthritis in Patients With Psoriasis. <i>Psoriasis Forum</i> , 2012 , 18, 2-10		5
67	Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. <i>Arthritis Research and Therapy</i> , 2011 , 13, R209	5.7	58
66	CD23(+)/CD21(hi) B-cell translocation and ipsilateral lymph node collapse is associated with asymmetric arthritic flare in TNF-Tg mice. <i>Arthritis Research and Therapy</i> , 2011 , 13, R138	5.7	34
65	Measuring intranodal pressure and lymph viscosity to elucidate mechanisms of arthritic flare and therapeutic outcomes. <i>Annals of the New York Academy of Sciences</i> , 2011 , 1240, 47-52	6.5	8
64	High-resolution interleaved water-fat MR imaging of finger joints with chemical-shift elimination. <i>Journal of Magnetic Resonance Imaging</i> , 2011 , 33, 245-51	5.6	3
63	Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. <i>Arthritis and Rheumatism</i> , 2011 , 63, 939-48		218
62	Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. <i>Journal of Rheumatology</i> , 2011 , 38, 2572-80	4.1	9
61	Summary of the International Federation of Psoriasis Associations (IFPA) meeting: a report from the GRAPPA 2009 annual meeting. <i>Journal of Rheumatology</i> , 2011 , 38, 530-9	4.1	1
60	GRAPPA Trainees Symposium 2009: a report from the GRAPPA 2009 annual meeting. <i>Journal of Rheumatology</i> , 2011 , 38, 526-9	4.1	6

59	Composite measures in psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010 , 37, 453-61	4.1	21
58	Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010 , 37, 448-52	4.1	14
57	Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010 , 37, 462-7	4.1	10
56	Comparative analysis of disease activity measures, use of biologic agents, body mass index, radiographic features, and bone density in psoriatic arthritis and rheumatoid arthritis patients followed in a large U.S. disease registry. <i>Journal of Rheumatology</i> , 2010 , 37, 2566-72	4.1	27
55	Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. <i>Arthritis Research and Therapy</i> , 2010 , 12, R113	5.7	59
54	CD16 (FcRgammalll) as a potential marker of osteoclast precursors in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R14	5.7	81
53	RANKL induces heterogeneous DC-STAMP(lo) and DC-STAMP(hi) osteoclast precursors of which the DC-STAMP(lo) precursors are the master fusogens. <i>Journal of Cellular Physiology</i> , 2010 , 223, 76-83	7	72
52	Mediation of nonerosive arthritis in a mouse model of lupus by interferon-alpha-stimulated monocyte differentiation that is nonpermissive of osteoclastogenesis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1127-37		29
51	Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2010 , 62, 917-28		96
50	High-resolution uniform MR imaging of finger joints using a dedicated RF coil at 3T. <i>Journal of Magnetic Resonance Imaging</i> , 2010 , 31, 240-7	5.6	9
49	The role of bone marrow edema and lymphangiogenesis in inflammatory-erosive arthritis. <i>Advances in Experimental Medicine and Biology</i> , 2010 , 658, 1-10	3.6	7
48	The diagnosis and treatment of early psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2009 , 5, 634-41	8.1	54
47	Translational perspectives on psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , 2009 , 83, 30-4		7
46	An 11-color flow cytometric assay for identifying, phenotyping, and assessing endocytic ability of peripheral blood dendritic cell subsets in a single platform. <i>Journal of Immunological Methods</i> , 2009 , 341, 106-16	2.5	27
45	Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2666-76		127
44	The quest for a biomarker of circulating osteoclast precursors. <i>Arthritis Research and Therapy</i> , 2009 , 11, 113	5.7	1
43	From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 94-105	4.5	87
42	Altered bone remodeling in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2008 , 10, 311-7	4.9	23

41	Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imaging. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2019-29		36
40	From skin to bone: translational perspectives on psoriatic disease. <i>Journal of Rheumatology</i> , 2008 , 35, 1434-7	4.1	22
39	Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. <i>Arthritis and Rheumatism</i> , 2007 , 56, 476-88		231
38	Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. <i>Arthritis and Rheumatism</i> , 2007 , 56, 4024-37		68
37	MRI and quantification of draining lymph node function in inflammatory arthritis. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1117, 106-23	6.5	49
36	Psoriatic disease--from skin to bone. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 698-706		64
35	Infliximab in psoriatic arthritis. <i>Future Rheumatology</i> , 2007 , 2, 13-22		2
34	National Psoriasis Foundation clinical consensus on disease severity. <i>Archives of Dermatology</i> , 2007 , 143, 239-42		106
33	Clinical development of anti-RANKL therapy. <i>Arthritis Research and Therapy</i> , 2007 , 9 Suppl 1, S7	5.7	107
32	Pathogenesis of Psoriatic Arthritis 2007 , 48-60		1
31	Radiographic progression in ankylosing spondylitis patients treated with infliximab. <i>Current Rheumatology Reports</i> , 2006 , 8, 253-4	4.9	
30	MRI outcomes in AS patients after two years of etanercept therapy. <i>Current Rheumatology Reports</i> , 2006 , 8, 253-4	4.9	2
29	The efficacy and safety of adalimumab in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2006 , 8, 329-329	4.9	3
28	The efficacy and safety of alefacept in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2006 , 8, 330-331	4.9	3
27	Metabolic disorders in patients with psoriasis and psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2006 , 8, 355-63	4.9	91
26	Efficacy and safety of infliximab for the treatment of psoriatic arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 300-1		3
25	Newer therapeutic approaches: spondyloarthritis and uveitis. <i>Rheumatic Disease Clinics of North America</i> , 2006 , 32, 75-90, viii	2.4	8
24	Autoimmunity and bone. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1068, 275-83	6.5	29

23	Therapies for psoriatic enthesopathy. A systematic review. <i>Journal of Rheumatology</i> , 2006 , 33, 1435-8	4.1	23
22	Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. <i>Journal of Rheumatology</i> , 2006 , 33, 1417-21	4.1	82
21	Treatment update on spondyloarthropathy. <i>Current Opinion in Rheumatology</i> , 2005 , 17, 247-56	5.3	23
20	Pathogenesis of psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2005 , 17, 406-12	5.3	41
19	Receptor activator of nuclear ??B ligand and osteoprotegerin: where are we now and what about future treatment uses?. <i>Current Opinion in Orthopaedics</i> , 2005 , 16, 370-375		3
18	Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3279-89		712
17	Doxycycline in undifferentiated spondyloarthropathy. <i>Current Rheumatology Reports</i> , 2005 , 7, 171-2; discussion 172	4.9	
16	Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. <i>Molecular Medicine</i> , 2005 , 11, 21-9	6.2	101
15	Assessment of patients with psoriatic arthritis: a review of currently available measures. <i>Arthritis and Rheumatism</i> , 2004 , 50, 24-35		151
14	Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. <i>Arthritis and Rheumatism</i> , 2004 , 50, 265-76		176
13	Treatment update on spondyloarthropathy. From NSAIDs and DMARDs to anti-TNF-alpha agents. <i>Postgraduate Medicine</i> , 2004 , 116, 31-6, 39-40	3.7	1
12	Pathogenesis of psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2004 , 16, 338-43	5.3	40
11	Etanercept in psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2003 , 3, 169-77	5.4	7
10	Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. <i>Journal of Clinical Investigation</i> , 2003 , 111, 821-31	15.9	187
9	Mechanisms of TNF-alpha and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. <i>Journal of Clinical Investigation</i> , 2003 , 111, 821-831	15.9	393
8	Pseudoxanthoma elasticum masquerading as Sjögren's syndrome. <i>Journal of Clinical Rheumatology</i> , 2002 , 8, 89-93	1.1	
7	Recent advances in the treatment of the seronegative spondyloarthropathies. <i>Current Rheumatology Reports</i> , 2001 , 3, 399-403	4.9	13
6	Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. <i>Arthritis Research</i> , 2000 , 2, 356-60		138

- 5 Alternative pathways of inflammation in rheumatoid arthritis. *Clinical Immunology Newsletter*, **1996**, 16, 57-62
- 4 Collagenase and stromelysin expression in rheumatoid synovium and cartilage: comment on the article by Wolfe et al. *Arthritis and Rheumatism*, **1994**, 37, 1831-3 1
- 3 Differential expression of the small inducible cytokines GRO alpha and GRO beta by synovial fibroblasts in chronic arthritis: possible role in growth regulation. *Cytokine*, **1994**, 6, 61-9 4 37
- 2 Quantitative electroencephalography. A new approach to the diagnosis of cerebral dysfunction in systemic lupus erythematosus. *Arthritis and Rheumatism*, **1992**, 35, 1330-42 36
- 1 Collagenase in synovitis of rheumatoid arthritis. *Seminars in Arthritis and Rheumatism*, **1992**, 22, 44-53 5:3 41